(EMAILWIRE.COM, January 25, 2019 ) Factors driving the growth of this market include technological advancements in prefilled syringes, the high prevalence of chronic diseases, the presence of a large patient population base, rising adoption of self-injection devices, and implementation of needlestick legislation.

Don’t miss out on business opportunities in Prefilled Syringes Market.

In addition, initiatives undertaken by leading market players (such as Gerresheimer AG, SCHOTT AG, and Becton, Dickinson and Company) to establish production facilities in both mature and developing markets have further added to the growth prospects of this market. However, lack of safety features in prefilled syringes and product recalls are expected to limit the growth of this market in the coming years.

Speak To Analyst:

https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=16618331

Prefilled Syringes Market, by Design

- Single-chamber
- Dual-chamber

Geographical Segmentation of Prefilled Syringes Market:

The market is segmented into four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World.

The increasing demand for self-administered treatments and high penetration of self-injection devices, the growing aging population, increasing prevalence of diabetes, and huge patient population is the major factors driving market growth in the region.

Europe is estimated to dominate the global market. Factors such as the rising prevalence of chronic diseases, growth in the biologics and biosimilars market, technological advancements, geographical expansion by key manufacturers, rising aging population, and high adoption of self-injection devices are driving the growth in the European market. The Asia-Pacific market is expected to grow at the highest CAGR during the forecast period.

Download PDF: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=16618331

key players operating in the prefilled syringes market:

Becton, Dickinson and Company (U.S.), Gerresheimer (Germany), SCHOTT AG (Germany), West Pharmaceutical Services, Inc. (U.S.), Ompi (Italy), Catalent, Inc. (U.S.), Weigao Group (China), Vetter Pharma International GmbH (Germany), Nipro Corporation (Japan), and MedPro Inc. (U.S.)